52122
document
Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery . OBJECTIVES Roux-en-Y gastric bypass surgery is the most commonly performed procedure for the treatment of morbid obesity . This anatomical alteration may affect the absorption and consequently the bioavailability of oral drugs . This study aims to investigate the oral bioavailability of moxifloxacin in 12 healthy volunteers who underwent gastric bypass surgery . PATIENTS AND METHODS In this randomized crossover study , each subject received two single standard doses of 400 mg of moxifloxacin orally or intravenously administered on two occasions separated by a washout period of 1 week . Serial venous blood samples were drawn up to 72 h after dosing and moxifloxacin plasma levels were measured by a validated HPLC method with fluorescence detection . [ clinicaltrials.gov database ( identifier : NCT01130922 ) . ] RESULTS After oral dosing , moxifloxacin plasma concentrations reached a maximum ( C ( max ) ) of 3.38 ± 1.41 mg/L after 1.75 h ( 0.75-4.00 ) . After intravenous dosing , C ( max ) and T ( max ) were 4.53 ± 1.43 mg/L and 1.03 h ( 0.75-2.50 ) , respectively . The mean areas under the plasma concentration time curve extrapolated to infinity ( AUC ( ∞ ) ) were 46.2 ± 1.4 mg · h/L after oral dosing and 52.3 ± 1.3 mg · h/L after intravenous dosing , resulting in a mean oral bioavailability of 88.32 % [ 90 % confidence interval ( CI ) 85.64 % -91.08 % ] . CONCLUSIONS This study confirms that exposure to moxifloxacin is equivalent for oral and intravenous administration of 400 mg dosages in healthy volunteers who underwent gastric bypass surgery . But these exposures were more than 50 % higher than those described for subjects without gastric bypass . This may suggest a higher enterohepatic recirculation of moxifloxacin after gastric bypass .
52123
Intervention_Pharmacological
moxifloxacin
52124
Intervention_Surgical
Roux-en-Y gastric bypass surgery
52125
Intervention_Surgical
Roux-en-Y gastric bypass surgery
52126
Intervention_Pharmacological
moxifloxacin
52127
Intervention_Surgical
gastric bypass surgery
52128
Intervention_Pharmacological
400 mg of moxifloxacin orally or intravenously
52129
Intervention_Pharmacological
moxifloxacin
52130
Intervention_Pharmacological
moxifloxacin
52131
Outcome_Physical
moxifloxacin plasma levels
52132
Outcome_Physical
moxifloxacin plasma concentrations
52133
Participant_Condition
12 healthy volunteers who underwent gastric bypass surgery .